Results 101 to 110 of about 4,863 (192)

Effects of quercetin on signaling proteins (PSTAT3, pERK1/2, pAKT) and interleukin-6 gene expression in prostate cancer pc3 cells [PDF]

, 2017
Background and purpose: Interleukin-6 (IL-6) causes the progression of prostate cancer through pSTAT3, pERK1/2, and pAKT cell signaling proteins. Quercetin, an herbal antioxidant, has antitumor effect. The aim of this study was to evaluate the effects of
Abbasi-Veldani, Akram., Amini, Sayed Asadollah., Ghatreh-Samani, Keihan., Heidarian, Esfandiar.   +3 more
core  

STAT3 in the systemic inflammation of cancer cachexia [PDF]

, 2016
Weight loss is diagnostic of cachexia, a debilitating syndrome contributing mightily to morbidity and mortality in cancer. Most research has probed mechanisms leading to muscle atrophy and adipose wasting in cachexia; however cachexia is a truly systemic
Bonetto, Andrea, Fishel, Melissa L., Zimmers, Teresa A.   +2 more
core   +1 more source

Citrullination of histone H3 drives IL-6 production by bone marrow mesenchymal stem cells in MGUS and multiple myeloma [PDF]

, 2016
Multiple myeloma (MM), an incurable plasma cell malignancy, requires localisation within the bone marrow. This microenvironment facilitates crucial interactions between the cancer cells and stromal cell types that permit the tumour to survival and ...
A Carrillo-Vico, A Ishigami, AA Rus'd, B Arnulf, B Zdzisinska, C Foulquier, C Ludwig, CJ Dreyton, CM Koch, CS Mitsiades, D Chauhan, E Tian, ER Vossenaar, ER Vossenaar, GL Cuthbert, H Yasui, HI Sati, HJ Cohen, J Corre, J San-Miguel, JJ van Beers, JL McElwee, JM Wettenhall, K Bommert, K Podar, L Chiecchio, L Garderet, M Garayoa, N Dezorella, O Landgren, O Landgren, PM Voorhees, PW Derksen, RA Kyle, S Wang, S Yaccoby, SA Bergfeld, SR Wallace, T Hayashi, T Hideshima, T Hideshima, T Otsuki, WC Cheung, X Zhang, Y Lu, Y Wang, YW Qiang   +46 more
core   +3 more sources

C071 | PATTERNS OF USAGE AND EFFICACY OF SILTUXIMAB IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE IN ITALY

Haematologica
Siltuximab has been approved for the treatment of idiopathic multicentric Castleman disease (iMCD) by the Food and Drug Administration in 2014 and it has been made available in Italy thereafter, initially via a named-patient program.
A. Broccoli, L. Argnani, S. Corazza, L. Arcaini, A.M. Barbui, F. Bellisario, R. Bruna, C. Califano, C. Campo, E. Cencini, G. Cetani, A. D’alessio, S. De Lorenzo, A. Di Rocco, S. Ferrero, A. Figuera, V. Innao, M. Marchetti, F. Marino, E.A. Martino, M. Miglino, L. Nassi, A. Pantaleo, T. Perrone, C. Plenteda, A. Rago, G.M. Rigolin, R. Scarpa, P.M. Stefani, F. Vianello, P.L. Zinzani   +30 more
doaj  

Novel agents in the treatment of multiple myeloma: a review about the future

Journal of Hematology & Oncology, 2016
Multiple myeloma (MM) is a disease that affects plasma cells and can lead to devastating clinical features such as anemia, lytic bone lesions, hypercalcemia, and renal disease.
Leonard Naymagon, Maher Abdul-Hay
doaj   +1 more source

Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-α-positive breast cancer

Breast Cancer: Targets and Therapy, 2016
Tineke Casneuf,1 Amy E Axel,2 Peter King,2 John D Alvarez,2 Jillian L Werbeck,3 Tinne Verhulst,1 Karin Verstraeten,1 Brett M Hall,2 A Kate Sasser2 1Janssen Research and Development, Beerse, Belgium; 2Janssen Research and Development, Spring House, PA ...
Casneuf T, Axel AE, King P, Alvarez JD, Werbeck JL, Verhulst T, Verstraeten K, Hall BM, Sasser AK   +8 more
doaj  

Update and new approaches in the treatment of Castleman disease

Journal of Blood Medicine, 2016
Kah-Lok Chan,1 Stephen Lade,2 H Miles Prince,1,3 Simon J Harrison1,3 1Department of Haematology, 2Department of Anatomical Pathology, Peter MacCallum Cancer Centre, 3Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC,
Chan KL, Lade S, Prince HM, Harrison SJ
doaj  

Chronic Myelomonocytic Leukemia Associated With TAFRO Syndrome-Like Symptoms

Annals of Internal Medicine: Clinical Cases
Thrombocytopenia, anasarca, fever, reticulin fibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome is a recent disease concept whose physiopathology remains largely unknown.
Issam Drici-Tani, Lucile Grange, Martin Killian, Jean-Baptiste Gaultier, Michel Péoc'h, Manon Sapet, Ludovic Fouillet, Emmanuelle Tavernier-Tardy, Émilie Chalayer   +8 more
doaj   +1 more source

A Review of the Role of Interleukin-6 on Disease Progression in Epithelial Ovarian Cancer [PDF]

, 2017
Ovarian cancer is one of the most harmful gynecological cancers and has one of the highest mortality rates. As ovarian cancer progresses, the patient has changes to the immune system and energy metabolism with symptoms being weight loss, nausea, and ...
Chaudhuri, Urmimala
core   +1 more source

Glucocorticoids/siltuximab/tocilizumab [PDF]

Reactions Weekly, 2021
openaire   +1 more source